Ischemic heart disease, factor predisposing to Barrett's adenocarcinoma: A case control study
- PMID: 25133047
- PMCID: PMC4133444
- DOI: 10.4292/wjgpt.v5.i3.183
Ischemic heart disease, factor predisposing to Barrett's adenocarcinoma: A case control study
Abstract
Aim: To define the significance of ischemic heart disease (IHD) (stable angina to infarction) co-existance in Barrett esophagus (BE) patients and patients with esophageal adenocarcinoma (AdE).
Methods: All BE/AdE patients in Blackpool-Wyre-Fylde area and Trikala prefecture identified from medical records. Patient clinical details were obtained from hospital and General Practitioner records. Additional information was gathered from validated questionnaire.
Results: Forty (33%) AdE and 83 (19%) BE patients had IHD (P = 0.002). Eighteen (15%) AdE and 34 (8%) BE patients had suffered a myocardial infarction (P = 0.03). Three (3%) AdE and 7 (2%) BE patients had severe heart failure (P = 0.82). Thirty-nine (47%) BE with IHD and 8 (20%) AdE patients with IHD consumed aspirin daily (P = 0.004). Seventh-seven (93%) BE patients with IHD and 36 (90%) AdE patients with IHD were on statins (P = 0.86). Logistic regression analysis: AdE was more frequent in the elderly, with long term reflux, long BE and concurrent IHD (odds ratio: 2.086, P = 0.001) not consuming statins. Eighteen (22%) BE patients with IHD [16 (84%) with myocardial infarction] vs 33 (10%) without IHD died from non-neoplastic causes within 24 mo from BE diagnosis (P = 0.005).
Conclusion: IHD is more prevalent in AdE than BE patients. Increased prevalence of AdE is related with the presence of myocardial infarction but not severe heart failure, possibly because patients with BE and severe IHD have low life expectancy.
Keywords: Barrett esophagus; Esophageal adenocarcinoma; Ischemic heart disease; Myocardial infarction; Non-steroidal anti-inflammatory drugs.
Similar articles
-
Daily use of non-steroidal anti-inflammatory drugs is less frequent in patients with Barrett's oesophagus who develop an oesophageal adenocarcinoma.Aliment Pharmacol Ther. 2004 Sep 15;20(6):645-55. doi: 10.1111/j.1365-2036.2004.02150.x. Aliment Pharmacol Ther. 2004. PMID: 15352913
-
Nonsteroidal anti-inflammatory drugs and statins have chemopreventative effects in patients with Barrett's esophagus.Gastroenterology. 2011 Dec;141(6):2000-8; quiz e13-4. doi: 10.1053/j.gastro.2011.08.036. Epub 2011 Aug 28. Gastroenterology. 2011. PMID: 21878200
-
Determination of risk for Barrett's esophagus and esophageal adenocarcinoma.Curr Opin Gastroenterol. 2016 Jul;32(4):319-24. doi: 10.1097/MOG.0000000000000274. Curr Opin Gastroenterol. 2016. PMID: 27276368 Review.
-
Reflux control is important in the management of Barrett's Esophagus: results from a retrospective 1,830 patient cohort.Surg Endosc. 2015 Dec;29(12):3528-34. doi: 10.1007/s00464-015-4103-3. Epub 2015 Feb 13. Surg Endosc. 2015. PMID: 25676204
-
Nonsteroidal anti-inflammatory drugs and esophageal inflammation - Barrett's esophagus - adenocarcinoma sequence: a meta-analysis.Dis Esophagus. 2011 Jul;24(5):318-24. doi: 10.1111/j.1442-2050.2010.01153.x. Epub 2010 Dec 17. Dis Esophagus. 2011. PMID: 21166737 Review.
Cited by
-
Role of chemoprophylaxis with either NSAIDs or statins in patients with Barrett's esophagus.World J Gastrointest Pharmacol Ther. 2014 Feb 6;5(1):27-39. doi: 10.4292/wjgpt.v5.i1.27. World J Gastrointest Pharmacol Ther. 2014. PMID: 24605249 Free PMC article. Review.
References
-
- Pope CE. Acid-reflux disorders. N Engl J Med. 1994;331:656–660. - PubMed
-
- Spechler SJ, Goyal RK. The columnar-lined esophagus, intestinal metaplasia, and Norman Barrett. Gastroenterology. 1996;110:614–621. - PubMed
-
- Cook MB, Wild CP, Everett SM, Hardie LJ, Bani-Hani KE, Martin IG, Forman D. Risk of mortality and cancer incidence in Barrett’s esophagus. Cancer Epidemiol Biomarkers Prev. 2007;16:2090–2096. - PubMed
-
- Auvinen MI, Sihvo EI, Ruohtula T, Salminen JT, Koivistoinen A, Siivola P, Rönnholm R, Rämö JO, Bergman M, Salo JA. Incipient angiogenesis in Barrett’s epithelium and lymphangiogenesis in Barrett’s adenocarcinoma. J Clin Oncol. 2002;20:2971–2979. - PubMed
-
- Amelink A, Haringsma J, Sterenborg HJ. Noninvasive measurement of oxygen saturation of the microvascular blood in Barrett’s dysplasia by use of optical spectroscopy. Gastrointest Endosc. 2009;70:1–6. - PubMed
LinkOut - more resources
Full Text Sources
Other Literature Sources